CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 35,376	$ 25,737
Research and development incentive receivable	998	1,744
Prepaid expenses and other current assets	289	177
Total current assets	36,663	27,658
Property and equipment, net	123	135
Research and development incentive receivable, net of current portion	632
Deferred tax asset	157	158
Other assets	1,111	1,111
Total assets	38,686	29,062
Current liabilities:
Accounts payable	4,130	2,622
Accrued expenses	1,715	3,461
Total current liabilities	5,845	6,083
Non Current liabilities:
Warrant liability	16,713	11,862
Total liabilities	22,558	17,945
Commitments and contingencies (Note 10)
Stockholders' equity:
Common stock, $0.001 par value; 100,000,000 shares authorized; 14,500,681 and 12,354,014 shares issued and outstanding as of March 31, 2018 and December 31, 2017, respectively	15	12
Additional paid-in capital	157,290	141,770
Accumulated other comprehensive loss	(158)	(268)
Accumulated deficit	(141,019)	(130,397)
Total stockholders' equity	16,128	11,117
Total liabilities, convertible preferred stock and stockholders' equity	$ 38,686	$ 29,062